- Home
- PLUG vs DNLI Comparison
PLUG vs DNLI Comparison
Compare PLUG & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | DNLI |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PLUG | DNLI |
|---|---|---|
| Price | $2.24 | $17.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $2.15 | ★ $32.58 |
| AVG Volume (30 Days) | ★ 106.0M | 1.7M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $676,169,000.00 | N/A |
| Revenue This Year | $13.86 | N/A |
| Revenue Next Year | $21.99 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.53 | N/A |
| 52 Week Low | $0.69 | $10.57 |
| 52 Week High | $4.58 | $24.35 |
Technical Indicators
Market Signals| Indicator | PLUG | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 46.76 |
| Support Level | $1.89 | $17.20 |
| Resistance Level | $2.46 | $18.30 |
| Average True Range (ATR) | 0.16 | 1.03 |
| MACD | 0.05 | -0.27 |
| Stochastic Oscillator | 62.50 | 6.73 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.